https://orcid.org/0000-0002-8682-7476
References
- Styczynski J, van der Velden W, Fox CP, et al.; Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth european conference on infections in leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7):803–811.
- Romero S, Montoro J, Guinot M, et al. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. Leuk Lymphoma. 2019;60(1):142–150.
- Styczynski J, Tridello G, Gil L, et al. Impact of donor Epstein-Barr virus serostatus on the incidence of Graft-Versus-Host disease in patients with acute leukemia after hematopoietic Stem-Cell transplantation: a study from the acute leukemia and infectious diseases working parties of the european society for blood and marrow transplantation. J Clin Oncol. 2016;34(19):2212–2220.
- Kołodziejczak M, Gil L, de la Camara R, et al.; Infectious Diseases Working Party, European Society for Blood and Marrow Transplantation. Impact of donor and recipient Epstein-Barr virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and Meta-analysis. Ann Hematol. 2021;100(3):763–777.
- Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-Host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401 e1.
- Raberahona M, Wackenheim C, Germi R, et al. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy. Transpl Infect Dis. 2016;18(6):889–895.
- Solano C, Mateo EM, Perez A, et al. Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: is it of any clinical usefulness? J Clin Virol. 2017;97:26–32.
- Rezvani K, Champlin RE. Epstein-Barr virus and B cells in the pathogenesis of Graft-Versus-Host disease after allogeneic hematopoietic Stem-Cell transplantation. J Clin Oncol. 2016;34(19):2201–2202.
- Burns DM, Tierney R, Shannon-Lowe C, et al. Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event. Blood. 2015;126(25):2665–2675.
- Ru Y, Zhang X, Song T, et al. Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes. Bone Marrow Transplant. 2020;55(9):1754–1762.
- Ahmad I, Cau NV, Kwan J, et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation. 2009;87(8):1240–1245.
- van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99(12):4364–4369.
- van der Velden WJ, Mori T, Stevens WB, et al. Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab. Bone Marrow Transplant. 2013;48(11):1465–1471.
- Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756–762.
- Jain T, Kosiorek HE, Grys TE, et al. Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation. Leuk Lymphoma. 2019;60(1):110–117.
- Omar H, Hagglund H, Gustafsson-Jernberg A, et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis. 2009;11(5):393–399.